JP7041673B2 - Ｎ－アシルエタノールアミド誘導体およびその使用 - Google Patents

Ｎ－アシルエタノールアミド誘導体およびその使用 Download PDF

Info

Publication number
JP7041673B2
JP7041673B2 JP2019520031A JP2019520031A JP7041673B2 JP 7041673 B2 JP7041673 B2 JP 7041673B2 JP 2019520031 A JP2019520031 A JP 2019520031A JP 2019520031 A JP2019520031 A JP 2019520031A JP 7041673 B2 JP7041673 B2 JP 7041673B2
Authority
JP
Japan
Prior art keywords
pea
item
compound
acid
acylethanolamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019520031A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019532069A (ja
JP2019532069A5 (enExample
Inventor
アンドリュー ディー． レビン，
Original Assignee
カーノット， エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by カーノット， エルエルシー filed Critical カーノット， エルエルシー
Publication of JP2019532069A publication Critical patent/JP2019532069A/ja
Publication of JP2019532069A5 publication Critical patent/JP2019532069A5/ja
Application granted granted Critical
Publication of JP7041673B2 publication Critical patent/JP7041673B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/17—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/18—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/17—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/20—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a carbon atom of an acyclic unsaturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/091—Esters of phosphoric acids with hydroxyalkyl compounds with further substituents on alkyl
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
    • C07H13/02—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
    • C07H13/04—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals attached to acyclic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Anesthesiology (AREA)
  • Cardiology (AREA)
JP2019520031A 2016-10-13 2017-10-12 Ｎ－アシルエタノールアミド誘導体およびその使用 Active JP7041673B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662407796P 2016-10-13 2016-10-13
US62/407,796 2016-10-13
US201762517344P 2017-06-09 2017-06-09
US62/517,344 2017-06-09
PCT/US2017/056353 WO2018071679A1 (en) 2016-10-13 2017-10-12 N-acylethanolamide derivatives and uses thereof

Publications (3)

Publication Number Publication Date
JP2019532069A JP2019532069A (ja) 2019-11-07
JP2019532069A5 JP2019532069A5 (enExample) 2020-11-19
JP7041673B2 true JP7041673B2 (ja) 2022-03-24

Family

ID=61906457

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019520031A Active JP7041673B2 (ja) 2016-10-13 2017-10-12 Ｎ－アシルエタノールアミド誘導体およびその使用

Country Status (7)

Country Link
US (2) US10933037B2 (enExample)
EP (1) EP3526215A4 (enExample)
JP (1) JP7041673B2 (enExample)
CN (1) CN110023308A (enExample)
AU (2) AU2017341769B2 (enExample)
CA (1) CA3040258A1 (enExample)
WO (1) WO2018071679A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017341769B2 (en) * 2016-10-13 2021-11-11 Carnot, Llc N-Acylethanolamide derivatives and uses thereof
WO2019213333A1 (en) * 2018-05-04 2019-11-07 Carnot2, Llc Combination therapies with edaravone and prodrugs of edaravone that are orally bioavailable and have altered pharmacokinetic properties
WO2019213335A1 (en) * 2018-05-04 2019-11-07 Carnot2, Llc Orally bioavailable prodrugs of edaravone with altered pharmacokinetic properties and methods of use thereof
US20220162239A1 (en) * 2019-02-21 2022-05-26 Université Claude Bernard Lyon 1 Structured molecular vectors for anti-inflammatory compounds and uses thereof
GB202103884D0 (en) 2021-03-19 2021-05-05 Eliem Therapeutics Uk Ltd Novel process
CN113304683B (zh) * 2021-06-17 2022-12-13 江南大学 葡糖酰胺封端聚醚型表面活性剂、其制备方法及应用
WO2025185743A1 (en) * 2024-03-07 2025-09-12 Centre for Chinese Herbal Medicine Drug Development Limited N-oleoylethanolamide and eubacterium rectale for use in treating diarrhea-predominant irritable bowel syndrome

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002535251A (ja) 1999-03-11 2002-10-22 アーデニア・インベストメンツ・リミテッド 癌治療のための新規化合物
JP2003526614A (ja) 1999-03-16 2003-09-09 アーデニア・インベストメンツ・リミテッド 多価不飽和脂肪酸誘導体およびその使用
JP2004268437A (ja) 2003-03-10 2004-09-30 Konica Minolta Holdings Inc インクジェット記録用紙
JP2011509074A (ja) 2007-12-19 2011-03-24 オズ ビオスイヤーンス 活性剤を細胞内に輸送するためのカチオン性脂質の新規なクラス
WO2014197880A1 (en) 2013-06-07 2014-12-11 Loma Linda University Dietary omega-3 fatty acid derived glycerophospholipids to treat neuropathic pain
US20150157733A1 (en) 2012-12-13 2015-06-11 Epitech Group S.R.L. Polyethylene glycol derivatives of palmitoylethanolamide and analogous acylethanolamides

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2440361A (en) * 1947-08-12 1948-04-27 Lilly Co Eli Process and culture media for the production of penicillin
DE4127471A1 (de) * 1991-08-20 1993-02-25 Henkel Kgaa Verwendung von aminoalkanolamidestern als verarbeitungshilfsmittel fuer thermoplastische kunststoffe
IT1271623B (it) * 1994-03-21 1997-06-04 Lifegroup Spa N-acilderivati di aminoalcoli con acidi monocarbossilici e bicarbossilici con attivita' neuroprotettiva nelle patologie neurologiche correlate ad eccitotossicita'
IT1271266B (it) * 1994-12-14 1997-05-27 Valle Francesco Della Impiego terapeutico di ammidi di acidi mono e bicarbossilici con amminoalcoli,selettivamente attive sul recettore periferico dei cannabinoidi
JP4015710B2 (ja) * 1995-05-31 2007-11-28 生化学工業株式会社 新規擬似糖脂質
NZ336538A (en) * 1996-10-15 2001-11-30 Liposome Co Inc N-acyl phosphatidylethanolamine-mediated liposomal drug delivery
US7090903B2 (en) * 2002-10-07 2006-08-15 Konica Corporation Ink-jet recording sheet
AU2017341769B2 (en) 2016-10-13 2021-11-11 Carnot, Llc N-Acylethanolamide derivatives and uses thereof

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002535251A (ja) 1999-03-11 2002-10-22 アーデニア・インベストメンツ・リミテッド 癌治療のための新規化合物
JP2003526614A (ja) 1999-03-16 2003-09-09 アーデニア・インベストメンツ・リミテッド 多価不飽和脂肪酸誘導体およびその使用
JP2004268437A (ja) 2003-03-10 2004-09-30 Konica Minolta Holdings Inc インクジェット記録用紙
JP2011509074A (ja) 2007-12-19 2011-03-24 オズ ビオスイヤーンス 活性剤を細胞内に輸送するためのカチオン性脂質の新規なクラス
US20150157733A1 (en) 2012-12-13 2015-06-11 Epitech Group S.R.L. Polyethylene glycol derivatives of palmitoylethanolamide and analogous acylethanolamides
WO2014197880A1 (en) 2013-06-07 2014-12-11 Loma Linda University Dietary omega-3 fatty acid derived glycerophospholipids to treat neuropathic pain

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
Gizzi et. al.，Molecular Tailored Histidine-Based Complexing Surfactants: From Micelles to Hydrogels，European Journal of Organic Chemistry ，2009年，23,，3953-3963
Luongo, Elvira; Russo, Roberto; Avagliano, Carmen; Santoro, Anna; Melisi, Daniela; Orefice, Nicola Salvatore; Raso, Giuseppina Mattace; Meli, Rosaria; Magliocca, Salvatore; Nieddu, Maria; Santiago, Gilvandete Maria Pinheiro; Boatto, Gianpiero; Calignano, Antonio; Rimoli, Maria Grazia，Galactosyl prodrug of palmitoylethanolamide: Synthesis, stability, cell permeation and cytoprotective activity，European Journal of Pharmaceutical Sciences，2014年，62，33-39
Pubchem，CID 10309854 Create Dates: 25 October 2006(25.10.2006) Date accessed; 19 June 2021(19.6.2021)
Pubchem，CID 24808239 Create Dates: 9 June 2008(9.6.2008) Date accessed; 19 June 2021(19.6.2021)
Sasaki, Atsushi; Murahashi, Naokazu; Yamada, Harutami; Morikawa, Anri，Syntheses of novel galactosyl ligands for liposomes and the influence of the spacer on accumulation in the rat liver，Biological & Pharmaceutical Bulletin，1995年，18(5),，740-6
Tarafdar, Pradip K.; Reddy, S. Thirupathi; Swamy, Musti J.，Nonclassical Odd-even Alternation in Mixed-Chain Diacylethanolamines: Implications of Polymorphism，Crystal Growth & Design ，2012年，12(3),，1132-1140

Also Published As

Publication number Publication date
AU2017341769B2 (en) 2021-11-11
US11547681B2 (en) 2023-01-10
US20190262288A1 (en) 2019-08-29
JP2019532069A (ja) 2019-11-07
US10933037B2 (en) 2021-03-02
CA3040258A1 (en) 2018-04-19
EP3526215A1 (en) 2019-08-21
CN110023308A (zh) 2019-07-16
AU2021273632A1 (en) 2021-12-16
EP3526215A4 (en) 2020-05-27
WO2018071679A1 (en) 2018-04-19
US20210093589A1 (en) 2021-04-01
AU2017341769A1 (en) 2019-05-02

Similar Documents

Publication Publication Date Title
JP7041673B2 (ja) Ｎ－アシルエタノールアミド誘導体およびその使用
US10710987B2 (en) Hydrochloride salt form for EZH2 inhibition
US10786476B2 (en) Combination therapy
CN111315867A (zh) 合成烟酰胺核苷的方法
TW200533343A (en) Aminoalcohol compounds
JP2019532069A5 (enExample)
JP2008524218A (ja) ゲムシタビンのアミドプロドラック、組成物、及びそれらの使用
WO2019213335A1 (en) Orally bioavailable prodrugs of edaravone with altered pharmacokinetic properties and methods of use thereof
WO2019213333A1 (en) Combination therapies with edaravone and prodrugs of edaravone that are orally bioavailable and have altered pharmacokinetic properties
WO1995018817A1 (fr) Nouveaux derives de l'adenosine, leurs procedes de preparation, compositions pharmaceutiques les contenant
EP0215319B1 (en) Gem-dihalo-1,8-diamino-4-aza-octanes
CN112592379B (zh) 一种β-D-葡萄糖短链脂肪酸酯化合物及其制备方法和应用
EP0220409B1 (en) Gem-dihalo and tetrahalo-1,12-diamino-4,9-diaza-dodecanes
WO2019233366A1 (zh) 选择性a 2a受体拮抗剂
US20210238151A1 (en) Oxazolidinone hydroxamic acid derivatives
US20220235054A1 (en) Novel maleate salts of triazolopyrazine derivatives, compositions, methods of use, and processes of manufacturing the same
WO2019056375A1 (zh) 酸敏感的吉非替尼轴向取代酞菁硅配合物及其制备方法和在医药上的应用
WO2021138847A1 (en) Macrolide compound and its use of treatment chronic respiratory disease
TWI571459B (zh) A novel fluorinated diphenyl glycolate compound or a salt thereof
JP2012214416A (ja) 抗炎症性腸疾患剤
CN116323614A (zh) 用于治疗炎性和自身免疫性病症的rabeximod的硫羰酯衍生物
TW201943716A (zh) 吳茱萸次鹼類似物及其應用
WO1996006088A1 (en) Benzothiazolesulfonamide derivative having terminal cycloalkyl group and medicinal use thereof
JPWO2005005390A1 (ja) 新規酵素阻害剤
JPWO2002018344A1 (ja) 新規なエステル又はアミド誘導体

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201009

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201009

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210721

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210806

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211015

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220221

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220311

R150 Certificate of patent or registration of utility model

Ref document number: 7041673

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150